Form 4: Avidity Biosciences CFO Michael MacLean Exercises Options and Sells Shares
SEC Form 4
Michael MacLean, CFO of Avidity Biosciences, exercised stock options and sold 40,000 shares of common stock on March 13, 2024.
Summary
- On March 13, 2024, Michael MacLean, the Chief Financial Officer of Avidity Biosciences, exercised stock options to acquire 40,000 shares of common stock at a price of $8.82 per share.
- Simultaneously, MacLean sold 40,000 shares of common stock at a weighted-average price of $24.519 per share, with individual sales ranging from $24.44 to $24.67.
- Following these transactions, MacLean directly owns 44,093 shares of Avidity Biosciences common stock, which includes restricted stock units and shares acquired through the Employee Stock Purchase Plan.
- MacLean also holds options to purchase 244,427 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral. This is a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the actions of company executives. It is common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- Shareholders may interpret insider sales as a lack of confidence in the company, although this is a routine transaction.
- Employees may be interested in the stock activity of company executives.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: exercise of stock options and sale of common stock. |
| 05/14/2030 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.